These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20812570)

  • 1. [What do the Swedish Drug and Therapeutics Committees think about cost savings?].
    Furängen A; Anders C
    Lakartidningen; 2010 Jul 21-Aug 10; 107(29-31):1790; author reply 1790. PubMed ID: 20812570
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug committees are not necessary--therapeutic recommendations are issued anyway].
    Jönsson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181
    [No Abstract]   [Full Text] [Related]  

  • 3. [The drug committees will play a key role].
    Gennser M
    Lakartidningen; 1993 Nov; 90(46):4078, 4083. PubMed ID: 8259004
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lists presented by eight drug committees compared. The number of preparations varies. Similar views on the most expensive drugs].
    Bergman U; Myrhed M
    Lakartidningen; 1996 Apr; 93(15):1459-60. PubMed ID: 8667738
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug product selection by formulary committees in Sweden.
    Lilja J
    Am J Hosp Pharm; 1979 Aug; 36(8):1042, 1044. PubMed ID: 484560
    [No Abstract]   [Full Text] [Related]  

  • 7. Rational selection of H2-receptor antagonists for the hospital formulary. Roundtable discussion.
    Keeffe EB; Harper JM; LeMay A; Sherrin TP; Siepler JK
    Hosp Formul; 1991 Nov; 26 Suppl D():13-9. PubMed ID: 10136560
    [No Abstract]   [Full Text] [Related]  

  • 8. [Inspra and the drug benefits board: What is the role of the drug committees?].
    Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183
    [No Abstract]   [Full Text] [Related]  

  • 9. [LFN's evaluation of Inspra illustrates the need of drug committees!].
    Malmström R; Hjemdahl P
    Lakartidningen; 2005 May 30-Jun 5; 102(22):1751-2. PubMed ID: 15987055
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacy and Therapeutics committee. Cost-containment considerations.
    Hochla PK; Tuason VB
    Arch Intern Med; 1992 Sep; 152(9):1773-5. PubMed ID: 1520043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 12. How a CQI program improved aminoglycoside use in a community hospital.
    Wade WE; McCall CY
    Hosp Formul; 1995 Feb; 30(2):114-6. PubMed ID: 10140350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategy for developing a safe and cost-effective H2-receptor antagonist program.
    Quercia RA; Chow MS; Jay GT; Quintiliani R
    Hosp Formul; 1991 Nov; 26 Suppl D():20-4. PubMed ID: 10136561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criteria-based DUE aids in selection of preferred agent.
    Drea EJ
    Hosp Formul; 1991 Nov; 26 Suppl D():25-7. PubMed ID: 10136562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Issues in formulary management: therapeutic interchange. The value, cost, and quality of therapeutic interchange.
    Mahoney CD
    Hosp Formul; 1992 Oct; 27 Suppl 2():2-3. PubMed ID: 10122035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 17. Formularies: the role of pharmacy-and-therapeutics (P&T) committees.
    Summers KH; Szeinbach SL
    Clin Ther; 1993; 15(2):433-41; discussion 432. PubMed ID: 8519049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.
    Godman B; Wettermark B; Hoffmann M; Andersson K; Haycox A; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):65-83. PubMed ID: 19371180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target drug monitoring: a cost-effective service provided by staff pharmacists.
    Chrymko MM; Meyer JD; Kelly WN
    Hosp Pharm; 1994 Apr; 29(4):347, 350-2. PubMed ID: 10133463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.